m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG01664)
Name
PAI-2
Synonyms
N-Butyryl-DL-homoserine lactone; N-butanoyl-lhomoserine lactone; N-(2-oxooxolan-3-yl)butanamide; N-(2-oxotetrahydrofuran-3-yl)butanamide; N-Butyrylhomoserine lactone; 98426-48-3; N-(2-Oxotetrahydro-3-furanyl)butanamide; AC1L9ENE; SCHEMBL787006; Homoserine lactone, N-butanoyl-; N-Butanoyl-DL-homoserine lactone; VFFNZZXXTGXBOG-UHFFFAOYSA-N; LMFA08030002; AN-38291; N-Butyryl-DL-homoserine lactone, &gt
    Click to Show/Hide
Status
Discontinued in Phase 2
Structure
Formula
C8H13NO3
InChI
1S/C8H13NO3/c1-2-3-7(10)9-6-4-5-12-8(6)11/h6H,2-5H2,1H3,(H,9,10)
InChIKey
VFFNZZXXTGXBOG-UHFFFAOYSA-N
PubChem CID
443433
TTD Drug ID
D0D3VA
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Urokinase-type plasminogen activator (PLAU)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Urokinase-type plasminogen activator (PLAU) is a therapeutic target for PAI-2. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PAI-2 through regulating the expression of Urokinase-type plasminogen activator (PLAU). [1], [2]
References
Ref 1 METTL3 promotes colorectal cancer metastasis by stabilizing PLAU mRNA in an m6A-dependent manner. Biochem Biophys Res Commun. 2022 Jul 23;614:9-16. doi: 10.1016/j.bbrc.2022.04.141. Epub 2022 May 6.
Ref 2 Discovery of novel 2-(aminoheteroaryl)-thiazole-5-carboxamides as potent and orally active Src-family kinase p56(Lck) inhibitors. Bioorg Med Chem Lett. 2004 Dec 20;14(24):6061-6. doi: 10.1016/j.bmcl.2004.09.093.